Navigation Links
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohn's Disease
Date:8/21/2013

l remission (Mayo score of 2 or lower and no subscore higher than 1) at 52 weeks. In addition, a significantly greater proportion of patients receiving vedolizumab achieved mucosal healing (Mayo endoscopic subscore of 0 or 1) at six and 52 weeks, and glucocorticoid-free remission at 52 weeks, compared with placebo. Discussed in a separate publication, results from GEMINI II, a placebo-controlled induction and maintenance study in patients with CD, showed that vedolizumab demonstrated statistically significant improvement in the primary endpoint of clinical remission (Crohn's disease activity index [CDAI] score less than or equal to 150 points) at six weeks and at 52 weeks compared to placebo. At six weeks, no significant difference was observed in the co-primary endpoint of CDAI-100 response (greater than or equal to 100-point decrease in the CDAI score) between the vedolizumab and placebo groups. A significantly greater proportion of patients showed CDAI-100 response and glucocorticoid-free remission at 52 weeks.

GEMINI I and GEMINI II are part of the four-study GEMINI Studies™, studying vedolizumab in 2,700 patients in nearly 40 countries, making it the largest Phase 3 clinical trial program conducted to date simultaneously evaluating both CD and UC. Enrolled patients had failed at least one conventional therapy, including glucocorticoids, immunomodulators and/or a tumor necrosis factor-alpha (TNF-alpha) antagonist. TNF-alpha antagonist failure patients included those with inadequate response (primary non-responders), loss of response (secondary non-responders) or those who were intolerant.

"These clinical studies suggest that vedolizumab may have the potential to maintain clinical remission in the appropriate patients," said Asit Parikh, M.D., Ph.D., vice president, general medicine, Takeda. "Takeda has a strong legacy of researching and treating GI disorders globally, and vedolizumab represents our fo
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. 1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
2. Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study
3. Leadership Through Research Collaboration Is Reflected In Articles Published In Alzheimers Association Journal
4. Depression Study Published on BCM-95 Curcumin
5. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
6. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
7. BioElectronics New Patent Published
8. Benefits of Using Hologics Breast Tomosynthesis Mammography Technology Supported in Published Italian Study
9. Clinical Results for Orameds Oral Diabetes Treatment Published in Peer Reviewed Journal PLOS ONE
10. Study Published in European Radiology Further Supports the Use of Hologics Breast Tomosynthesis in Cancer Screening in Practices Using Double Reads
11. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... to their offering. Developed by Novo ... Novolog) is an important drug for the treatment ... as a fast- acting insulin analog, starts working ...
(Date:8/28/2015)... , Aug. 28, 2015  IP Shakti, LLC, today ... Logo - ... "Our new corporate identity signifies our transformation into ... first predictive analytics platform for patent claim validity." ... launch of the proprietary AIA Shield™ platform, the Company commenced ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015  Mylan ... its shareholders have approved Mylan,s proposed acquisition of ... and the related issuance of Mylan ordinary shares ... of shareholders held today. The transaction received the ... general meeting. In addition, the transaction received support ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... 2012 /PRNewswire-iReach/ -- infofree™, a leading provider of ... Credit Profiles and Email Lists for $49.95 per month, has ... can now select consumers that will turn various ages within ... as insurance, rely heavily on marketing to individuals of a ...
... 2012  The key to reducing the risk of short ... high and low blood sugar levels.  But, for the ... be a daily challenge.  Now, the new OneTouch® Verio™IQ ... easy to zero in on patterns of highs and ...
Cached Medicine Technology:infofree™ Now Offers Age as a Select for Insurance Leads 2First and Only Meter to Look for Patterns of High and Low Blood Sugar and Alert Diabetes Patients Right on Screen 2First and Only Meter to Look for Patterns of High and Low Blood Sugar and Alert Diabetes Patients Right on Screen 3First and Only Meter to Look for Patterns of High and Low Blood Sugar and Alert Diabetes Patients Right on Screen 4
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering music ... second year to the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. ... to support music education in the underfunded school districts of Mendon and its neighboring ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in the City, ... added yet another accolade to its cadre of widespread support—an official letter of support ... help of the medical community and the University of Illinois at Chicago’s Department of ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was ... the latest and coolest applications on the market for iOS, Android, and Windows. Joe ... with viewers how this software allows businesses to track product movement from beginning to ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman of ... The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military veterans ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... XTENT, Inc.,(Nasdaq: XTNT ) today reported financial results for ... company reported a net loss and net loss attributable to ... fourth quarter,of 2007, compared to a net loss and net ... share, for the same period in,2006. The company,s net loss ...
... , , TUESDAY, Feb. 19 (HealthDay News) -- Studies show no ... the sudden collapse of kidney function that carries with it ... analysis of 38 trials found no difference in the death ... method or another, according to a report in the ...
... reaction to sounds, might be way to spot hearing problems, study ... not just be a window to the soul, they may also ... , A new study reports that the eyes can provide clues ... may be especially helpful for diagnosing hearing problems in babies, very ...
... isotopes for peacetime uses at Oak Ridge National Laboratory ... by the American Chemical Society in a special ceremony ... Bruce E. Bursten, Ph.D., president of the Society, will ... director of ORNL. Bursten said the distribution of radioisotopes, ...
... Current Hospital, WALLA WALLA, Wash., Feb. 19 ... announced today the Department of,Veterans Affairs (VA) will ... health at the Walla Walla VA,Medical Center., ... the health care,needs of Washington,s veterans and recognizes ...
... Middle-aged women who suffered physical or sexual abuse as ... costs, according to a long-term study of more than 3,000 ... used health services at significantly higher rates than did non-abused ... with an average age in their late 40s still suffer ...
Cached Medicine News:Health News:XTENT Announces 2007 Financial Results 2Health News:XTENT Announces 2007 Financial Results 3Health News:XTENT Announces 2007 Financial Results 4Health News:XTENT Announces 2007 Financial Results 5Health News:XTENT Announces 2007 Financial Results 6Health News:No Difference Found in Treatments for Acute Kidney Failure 2Health News:No Difference Found in Treatments for Acute Kidney Failure 3Health News:Eyes a Window to Hearing Loss? 2Health News:Eyes a Window to Hearing Loss? 3Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 2Health News:Peacetime use of radioisotopes at Oak Ridge cited as Chemical Landmark 3Health News:Women who suffered child abuse spend more on health care 2Health News:Women who suffered child abuse spend more on health care 3
Optical Mini Urethrotome for telescope 3.3 mm, 0...
... The flexible cystoscope is being used more and ... to its outstanding optical quality and large working/irrigation ... diagnostics and therapy. The outstanding flexibility of the ... the patient. ...
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... System is the Next Generation thermotherapy ... BPH. Other thermotherapy systems treat patients ... effect of each patient's individual intraprostatic ... achieving the desired therapeutic temperatures and ...
Medicine Products: